Therapeia

Therapeia was an Australian biotechnology company focused on the development of localized radiation therapies for the treatment of solid tumors. The company's lead technology, OncoSil, is a brachytherapy device consisting of phosphorus-32 microparticles designed to be injected directly into tumors, such as those in the pancreas or liver. By delivering targeted beta radiation, the technology aims to provide high-dose radiotherapy while minimizing damage to surrounding healthy tissue. Therapeia was acquired in 2013 by OncoSil Medical (formerly NeuroDiscovery), which has since advanced the technology through clinical trials and regulatory approvals.